Chugai Of Japan Ties With U.S. Firm To Develop Key Hepatitis Drug
This article was originally published in PharmAsia News
Executive SummaryJapan's Chugai Pharmaceutical has signed an agreement with Romark Laboratories of the United States to develop a nitazoxanide drug to treat hepatitis C. The drug is in the relatively new class of thiazolide antiviral drugs invented by the chairman of Romark. The firm, already is developing thiazolides for other treatments, including hepatitis B. Few details of the tie-up were detailed beyond payment schedules. (Click here for more
You may also be interested in...
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.
Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.